Summary
Synopsis
Pentamidine isethionate,1 an aromatic diamidine, is an antiprotozoal agent proven to decrease mortality from Pneumocystis carinii pneumonia in debilitated infants and immunodeficient adults and children. Like the combination antimicrobial agent co-trimoxazole, pentamidine has been shown in retrospective studies to resolve episodes of pneumonia in approximately 41 to 87% of patients, including those with the acquired immunodeficiency syndrome (AIDS), when used alone or as sequential therapy.
Although about 45% of all patients given pentamidine experience side effects — which may include nephrotoxicity, hypotension, hypoglycaemia or local reactions — in patients with AIDS the incidence of side effects is less with pentamidine than with co-trimoxazole. Thus, despite its profile of potentially severe side effects, pentamidine isethionate is a proven antimicrobial agent with a distinct place in the treatment of Pneumocystis carinii pneumonia in the growing population of AIDS patients.
Antiprotozoal Activity
Quantitative analyses of the activity of pentamidine against P. carinii are lacking. However, in concentrations of 0.3 to 9 mg/L pentamidine decreases the viability of the organism in vitro. Doses of 10 or 20 mg/kg subcutaneously or 4 mg/kg intramuscularly daily or thrice weekly for 2 weeks prolonged the survival of rats with experimentally induced P. carinii pneumonia. Pentamidine inhibits P. carinii by a ‘cidal’ mechanism, thought to involve inhibition of one or more of the following: oxidative phosphorylation, nucleic acid and protein synthesis, glucose metabolism, or dihydrofolate reductase activity.
In vitro toxicity studies reveal that nephrotoxicity seen with pentamidine may result from the formation of nucleotide precipitates or from nucleic acid binding with subsequent depletion of adenosine triphosphate. Similarly, a direct cytotoxic effect of pentamidine on pancreatic β-islet cells is thought to precipitate hypoglycaemia (by initial insulin release) which may be followed by hyperglycaemia (via cytolysis and insulin depletion).
Pharmacokinetic Properties
Following an intramuscular dose of pentamidine 4 mg/kg to patients with malignant diseases, peak plasma concentrations of about 0.5 mg/L are attained in 1 hour. These concentrations are sustained for 24 hours, and the drug has been detected in the plasma of patients 6 to 8 weeks after administration. This is likely a reflection of the extensive tissue binding that occurs with pentamidine.
Studies in animals reveal that pentamidine is found in the kidney in double the quantities seen in the liver and 5 to 10 times those seen in the lung. In humans, the volume of distribution of pentamidine is estimated to be 3 L/kg.
Studies both in animals and in humans show that pentamidine does not undergo hepatic biotransformation. Thus, elimination is achieved by renal routes. Slow release of the drug from tissue compartments is probably responsible for its prolonged rate of elimination; in the presence of renal disease this may be further increased and thus dosage adjustment may be necessary.
Therapeutic Trials
Very few prospective trials have investigated the use of pentamidine in the treatment of P. carinii pneumonia; rather, the literature consists mostly of retrospective analyses of case reports. Several retrospective studies in patients with AIDS or other immunodeficiencies have assessed the efficacy rate of pentamidine 4 mg/kg administered once daily intravenously or intramuscularly for at least 10 days as the initial and only antimicrobial therapy of P. carinii pneumonia, or as replacement therapy in patients unresponsive to or who experienced adverse effects with co-trimoxazole. The results of studies which evaluated more than 15 patients of this type indicate an efficacy rate for pentamidine which ranges from 41 to 87%. In comparison, the efficacy rate observed with co-trimoxazole (trimethoprim 20 mg/kg plus sulphamethoxazole 100 mg/kg daily in divided doses orally or intravenously) as initial and only antimicrobial therapy in the same studies was 41 to 78%.
Patients with AIDS who are switched to pentamidine therapy because of adverse reactions to co-trimoxazole respond much better than those who receive the drug because of treatment failure with co-trimoxazole. However, concomitant therapy with both pentamidine and co-trimoxazole has not improved survival rates further than those achieved with either antimicrobial drug alone. A longer duration of therapy with pentamidine may be required in patients with AIDS than in those without AIDS, and relapse is more common.
Higher efficacy rates for both pentamidine and co-trimoxazole have been achieved in the small number of prospective, randomised trials which compared responses to either drug in a few AIDS and non-AIDS patients, than in retrospective studies. This may be a result of such factors as better methodology or improved patient care in the prospective trials.
Side Effects
About 45% of all patients receiving pentamidine experience adverse reactions, which can be severe. Nephrotoxicity, hypotension and paradoxical hypoglycaemic-hyperglycaemic reactions are seen most frequently; leucopenia, abnormal liver function, hypocalcaemia and local irritation at the site of intramuscular injection can also occur.
Nevertheless, in patients with AIDS, pentamidine causes a lower incidence of adverse reactions than does co-trimoxazole (45% versus 65%, respectively).
Dosage and Administration
For adults and children, the dose of pentamidine given as the isethionate salt is 4 mg/kg once daily for at least 14 days, preferably by slow intravenous infusion over 60 minutes. If the drug is administered by deep intramuscular injection, splitting the dose may minimise the possibility of local reactions.
Patients should remain supine during administration of the drug, and careful clinical and laboratory monitoring of patient status during and after treatment is essential. In the presence of impaired renal function, pentamidine should be administered over a longer infusion time or on alternate days.
Similar content being viewed by others
References
Andersen R, Boedicker M, Ma M, Goldstein E. Adverse reactions associated with pentamidine isethionate in AIDS patients: recommendations for monitoring therapy. Drug Intelligence and Clinical Pharmacy 20: 862–868, 1986
Bartlett HS, Eichholtz R, Miller J, Smith JW. Activity of antimicrobial agents against Pneumocystis carinii (PC) in culture. Abstract no. 496, 23rd Meeting of the ICAAC, Las Vegas, October 24–26, 1983
Bellamy EA, Meller S, Westbury G, Heisband JE. CT demonstration of calcified subcutaneous masses following parenteral pentamidine isethionate injection. Journal of Computer Assisted Tomography 9: 210–211, 1985
Bennett WM, Muther RS, Parker RA, Feig P, Morrison G, et al. Drug therapy in renal failure: dosing guidelines for adults. Annals of Internal Medicine 93 (Part 1): 62–89, 1980
Boillot D, Veld P, Sai P, Feutren G, Gepts W, et al. Functional and morphological modifications induced in rat islets by pentamidine and other diamidines in vitro. Diabetologia 28: 359–364, 1985
Bornstein RS, Yarbro JW. An evaluation of mechanism of action of pentamidine isethionate. Journal of Surgical Oncology 2: 393–398, 1970
Bouchard P, Sai P, Reach G, Caubarrère I, Ganeval D. Diabetes mellitus following pentamidine-induced hypoglycemia in humans. Diabetes 31: 40–45, 1982
Burke BA, Good RA. Pneumocystis carinii infection. Medicine 52: 23–51, 1973
De NC, Alam AS, Kapoor JN. Stability of pentamidine isethionate in 5% dextrose and 0.9% sodium chloride injections. American Journal of Hospital Pharmacy 43: 1486–1488, 1986
Dennis T. Trimethoprim-sulfamethoxazole or pentamidine in the acquired immunodeficiency syndrome. Correspondence. Annals of Internal Medicine 105: 629–630, 1986
DeVita VT, Emmer M, Levine A, Jacobs B, Berard C. Pneumocystis carinii pneumonia. Successful diagnosis and treatment of two patients with associated malignant processes. New England Journal of Medicine 280: 287–291, 1969
Dieudonne JM. A calcifying topical reaction to mast cell depletors in the rat. Experientia 20: 209–210, 1964
Drake S, Lampasona V, Nicks HL, Schwarzmann SW. Pentamidine isethionate in the treatment of Pneumocystis carinii pneumonia. Clinical Pharmacy 4: 507–516, 1985
Dutz W, Post C, Jennings-Khodadad E, Fakouhi T, Kohout E, et al. Therapy and prophylaxis of Pneumocystis carinii pneumonia. National Cancer Institute Monograph 43: 179–184, 1976
Engelberg LA, Lerner CW, Tapper ML. Clinical features of Pneumocystis pneumonia in the acquired immune deficiency syndrome. American Review of Respiratory Diseases 130: 689–694, 1984
Finegold I. Oral desensitization to trimethoprim-sulfamethoxazole in a patient with AIDS. Journal of Allergy and Clinical Immunology 75 (Part 2): 137, 1985
Fitzgerald DB, Young IS. Pentamidine and hypoglycemia. Annals of Internal Medicine 99: 879, 1983
Fitzgerald DB, Young IS. Reversal of pentamidine-induced hypoglycaemia with oral diazoxide. Journal of Tropical Medicine and Hygiene 87: 15–19, 1984
Frenkel JK, Good JT, Schultz JA. Latent Pneumocystis infection of rats, relapse and chemotherapy. Laboratory Investigations 15: 1559–1577, 1966
Geelhoed GW, Hubbard SB, Powell RD, Doppman JL, DeVita Jr VT. Clinical characteristics of Pneumocystis carinii pneumonia. American Surgeon 45: 293–304, 1979
Gentry LO, Ruskin J, Remington JS. Pneumocystis carinii pneumonia. Problems in diagnosis and therapy in 24 cases. California Medicine 116: 6–14, 1972
Grant AM, Sandier RM, Carrell RW. Hypoglycaemic effect of pentamidine detected by glucose screen. Lancet 2: 510–511, 1977
Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Annals of Internal Medicine 100: 495–499, 1984
Haverkos HW. Assessment of therapy for Pneumocystis carinii pneumonia. American Journal of Medicine 76: 501–508, 1984
Heimick CG, Green JK. Pentamidine associated hypotension and route of administration. Annals of Internal Medicine 103: 480, 1985
Hughes WT. Pneumocystis carinii pneumonia. New England Journal of Medicine 297: 1381–1383, 1977
Hughes WT. Pneumocystis carinii pneumonitis. Chest 85: 810–813, 1984
Hughes WT, Feldman S, Chaudhary SC, Ossi MJ, Cox F, et al. Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. Journal of Pediatrics 92: 285–291, 1978
Hughes WT, Kim H-K, Price RA, Miller C. Attempts at prophylaxis for murine Pneumocystic carinii pneumonitis. Current Therapeutic Research 15: 581–587, 1973
Hughes WT, McNabb PC, Makres TD, Feldman S. Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis. Antimicrobial Agents and Chemotherapy 5: 289–293, 1974
Hyun BH, Varga F, Thalheimer LJ. Pneumocystis carinii pneumonitis occurring in an adopted Korean infant. Journal of the American Medical Association 195: 164–166, 1966
Ivády G, Páldy L, Koltay M, Tóth G, Kovács Z. Pneumocystis carinii pneumonia. Lancet 1: 616–617, 1967
Ivády G, Páldy L. Ein neues Behandlungsverfahren der interstitiellen plasmazelligen Pneumonie Frühgeborener mit fünfwertigem Stibium und aromatischen Diamidinen. Monatsschrift für Kinderheilkunde 106: 10, 1958
Ivády G, Páldy L, Unger G. A new form of treatment for interstitial plasma cell pneumonia with pentamidine. Monatsschrift für Kinderheilkund 11: 297–299, 1963
Ivády G, Páldy L. Treatment of Pneumocystis carinii pneumonia in infancy. National Cancer Institute Monograph 43: 201–208, 1976
Jackson DP, Kuhl Jr WJ, Irvin JL. The determination of aromatic amidines in plasma and urine. Journal of Biological Chemistry 167: 377–386, 1947
Jaffe HS, Abrams DI, Ammann AJ, Lewis BJ, Golden JA. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet 2: 1109–1111, 1983
Jha TK, Sharma VK. Pentamidine-induced diabetes mellitus. Transactions of the Royal Society of Tropical Medicine and Hygiene 78: 252–253, 1984
Jick H. Adverse reactions to trimethoprim-sulphamethoxazole in hospitalised patients. Review of Infectious Diseases 4: 426–428, 1982
Johnson HD, Johnson WW. Pneumocystis carinii pneumonia in children with cancer. Diagnosis and treatment. Journal of the American Medical Association 214: 1067–1073, 1970
Kempin SJ, Jackson CW, Edwards CC. In vitro inhibition of platelet function and coagulation by pentamidine isethionate. Antimicrobial Agents and Chemotherapy 12: 451–454, 1977
Kluge RM, Spaulding DM, Spain AJ. Combination of pentamidine and trimethoprim-sulfamethoxazole in the therapy of Pneumocystis carinii pneumonia in rats. Antimicrobial Agents and Chemotherapy 19: 975–978, 1978
Kopac MJ. The action of diamidines and related compounds on nucleoproteins. Cancer Research 7: 44–48, 1947
Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Annals of Internal Medicine 100: 663–671, 1984
Launoy L, Guillot M, Jonchère H. Étude du stockage et de l’elimination de la pentamidine chez la souris et la rat blanc. Annales Pharmaceutiques Françaises 18: 273–285, 1960
Lipson A, Marshall WC, Hayward AR. Treatment of Pneumocystis carinii pneumonia in children. Archives of Diseases in Childhood 52: 314–319, 1977
Makulu R, Waalkes PT. Interaction between aromatic diamidines and nucleic acids: possible implications for chemotherapy. Journal of the National Cancer Institute 54: 305–309, 1975
Marantz PR. Trimethoprim-sulfamethoxazole or pentamidine in the acquired immunodeficiency syndrome. Correspondence. Annals of Internal Medicine 105: 630, 1986
Marshall WC, Weston J, Bodian M. Pneumocystis carinii pneumonia (PCP) and congenital hypogamma-globulinaemia. Archives of Diseases in Childhood 39: 18–25, 1964
Mitsuyasu R, Groopman J, Volberding P. Cutaneous reaction to trimethoprim-sulfamethoxazole in patients with AIDS and Kaposi’s sarcoma. New England Journal of Medicine 308: 1535, 1983
Murray JF, Felton CP, Garay SM, Gottlieb MS, Hopewell PC, et al. Pulmonary complications of the acquired immunodeficiency syndrome. New England Journal of Medicine 310: 1682–1688, 1984
Murdoch JK, Keystone JS. Pentamidine and hypoglycemia. Annals of Internal Medicine 99: 819, 1983
Murphey SA, Josephs AS. Acute pancreatitis associated with pentamidine therapy. Archives of Internal Medicine 141: 56–58, 1981
Osei K, Falko JM, Nelson KP, Stephens R. Diabetogenic effects of pentamidine. In vitro and in vivo studies in a patient with malignant insulinoma. American Journal of Medicine 77: 41–46, 1984
Otterness IG, Torchia AJ, Doshan HD. Complement inhibition by amidines and guanidines — in vivo and in vitro results. Biochemical Pharmacology 27: 1873–1878, 1978
Patterson JH, Lindsey IL, Edwards ES, Logan Jr WD. Pneumocystis carinii pneumonia and altered host resistance: treatment of one patient with pentamidine isethionate. Pediatrics 38: 388–397, 1966
Pesanti EL. In vitro effects of antiprotozoan drugs and immune serum on Pneumocystis carinii. Journal of Infectious Diseases 141: 775–780, 1980
Pesanti EL, Cox C. Metabolic and synthetic activities of Pneumocystis carinii in vitro. Infection and Immunity 34: 908–914, 1981
Pifer LL, Pifer DD, Woods DR. Biological profile and response to anti-Pneumocystis agents of Pneumocystis carinii in cell culture. Antimicrobial Agents and Chemotherapy 24: 674–678, 1983
Raia JJ, Patton LR, Klein RA. Prolonged hypoglycemia during pentamidine therapy. Clinical Pharmacy 2: 505–506, 1983
Redman JC. Pneumocystis carinii pneumonia in an adopted Vietnamese infant. Journal of the American Medical Association 230: 1561–1563, 1974
Robbins JB, Miller RH, Arean VM, Pearson HA. Successful treatment of Pneumocystis carinii pneumonitis in a patient with congenital hypogammaglobulinaemia. New England Journal of Medicine 272: 708–713, 1965
Rosen PP, Martin N, Armstrong D. Pneumocystis carinii pneumonia (PCP): diagnosis by lung biopsy. American Journal of Medicine 58: 794–802, 1975
Salmeron S, Petitpretz P, Katlama C, Herve P, Brivet F, et al. Pentamidine and pancreatitis. Annals of Internal Medicine 105: 140–141, 1986
Sands M, Kron MA, Brown RB. Pentamidine: a review. Reviews of Infectious Diseases 7: 625–634, 1985
Sharpe SM. Pentamidine and hypoglycemia. Annals of Internal Medicine 99: 128, 1983
Shuster M, Dunn M. Pentamidine and hematuria. Annals of Internal Medicine 105: 146, 1986
Selik RM, Haverkos HW, Curran JW. Acquired immune deficiency syndrome (AIDS) trends in the United States, 1978–1982. American Journal of Medicine 76: 493–500, 1984
Siegel SE, Wolff LJ, Baehner RL, Hammond D. Treatment of Pneumocystis carinii pneumonitis. American Journal of Diseases of Children 138: 1051–1054, 1984
Small CB, Harris CA, Friedland GH, Klein RS. The treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Archives of Internal Medicine 145: 837–840, 1985
Smith E, Gáspár I. Pentamidine treatment of Pneumocystis carinii pneumonitis in an adult with lymphatic leukemia. American Journal of Medicine 44: 626–631, 1968
Spadafora M, Roberts JR. Hypoglycemic coma from pentamidine in an AIDS patient. American Journal of Emergency Medicine 4: 384, 1986
Stahl-Bayliss CM, Kaiman CM, Laskin OL. Pentamidine-induced hypoglycemia in patients with the acquired immune deficiency syndrome. Clinical Pharmacology and Therapeutics 39: 271–275, 1986
Stark FR, Crast F, Gemmer T, Ramirez R. Fatal Herxheimer reaction after pentamidine in Pneumocystis pneumonia. Lancet 1: 1193–1194, 1976
Stehr-Green JK, Heimick CG. Pentamidine and renal toxicity. New England Journal of Medicine 313: 694–695, 1985
Vanék J, Jirovec O, Lukes J. Interstitial plasma cell pneumonia in infants. Annals of Paediatrics 180: 1–21, 1953
Waalkes TP, Maluku DR. Pharmacologic aspects of pentamidine. National Cancer Institute Monograph 43: 171–176, 1976
Waalkes TP, DeVita VT. The determination of pentamidine (4,4′-diamidinophenoxypenlane) in plasma, urine, and tissues. Journal of Laboratory and Clinical Medicine 75: 871–878, 1970
Waalkes TP, Denham C, DeVita VT. Pentamidine: clinical pharmacologic correlations in man and mice. Clinical Pharmacology and Therapeutics 11: 505–512, 1970
Waldman RH, Pearce DE, Martin RA. Pentamidine isothionate levels in lungs, livers and kidneys of rats after aerosol or intramuscular administration. American Review of Respiratory Disease 108: 1004–1006, 1973
Walzer PD, Perl DP, Krogstad DJ, Rawson PG, Schultz MG. Pneumocystis carinii in the United States. Epidemiologic, diagnostic and clinical features. Annals of Internal Medicine 80: 83–93, 1974
Wang JJ, Freeman AI, Gaeta JF, Sinks LF. Unusual complications of pentamidine in the treatment of Pneumocystis carinii pneumonia. Journal of Pediatrics 77: 311–314, 1970
Waring MJ. The effects of antimicrobial agents on ribonucleic acid polymerase. Molecular Pharmacology 1: 1–13, 1965
Western KA, Perera DR, Schultz MG. Pentamidine isethionate in the treatment of Pneumocystis carinii pneumonia. Annals of Internal Medicine 73: 695–702, 1970
Western KA, Norman L, Kaufmann AF. Failure of pentamidine isethionate to provide chemoprophylaxis against Pneumocystis carinii infection in rats. Journal of Infectious Diseases 13: 273–276, 1975
Wharton JM, Coleman DL, Wofsy CB, Luce JM, Blumenfeld W, et al. Trimethoprim-sulphamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the Acquired Immunodeficiency Syndrome. Annals of Internal Medicine 105: 37–44, 1986
Wien R, Freeman W, Scotcher NM. The metabolic effects produced by certain aromatic diamidines. Annals of Tropical Medicine and Parasitology 37: 19–33, 1943
Wien R. The pharmacological actions of certain aromatic diamidines possessing trypanocidal activity. Annals of Tropical Medicine and Parasitology 37: 1–33, 1943
Author information
Authors and Affiliations
Additional information
Various sections of the manuscript reviewed by: W. Brumfitt, The Royal Free Hospital, London, England; E. De Clercq, Katholieke Universiteit, Rega Instituut, Leuven, Belgium; J.L. Harkness, Department of Microbiology, St Vincent’s Hospital, Darlinghurst, NSW, Australia; J.A. Hoogkamp-Korstanje, Laboratory for Public Health, Leeuwarden, The Netherlands; S. Lang, Department of Clinical Microbiology, Middlemore Hospital, Auckland, New Zealand; S.R. Norrby, Department of Infectious Diseases, University of Umeå, Umeå, Sweden.
‘Pentam 300’ (LyphoMed Inc.); ‘Pentamidine Isethionate’ (May & Baker).
Rights and permissions
About this article
Cite this article
Goa, K.L., Campoli-Richards, D.M. Pentamidine Isethionate. Drugs 33, 242–258 (1987). https://doi.org/10.2165/00003495-198733030-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198733030-00002